SG11201900328WA - Inhibitors of cyclin-dependent kinase 7 (cdk7) - Google Patents
Inhibitors of cyclin-dependent kinase 7 (cdk7)Info
- Publication number
- SG11201900328WA SG11201900328WA SG11201900328WA SG11201900328WA SG11201900328WA SG 11201900328W A SG11201900328W A SG 11201900328WA SG 11201900328W A SG11201900328W A SG 11201900328WA SG 11201900328W A SG11201900328W A SG 11201900328WA SG 11201900328W A SG11201900328W A SG 11201900328WA
- Authority
- SG
- Singapore
- Prior art keywords
- quebec
- international
- avenue
- cdk7
- cyclin
- Prior art date
Links
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 title abstract 2
- 101710106276 Cyclin-dependent kinase 7 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101150059448 cdk7 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 206010060999 Benign neoplasm Diseases 0.000 abstract 1
- 102000016736 Cyclin Human genes 0.000 abstract 1
- 108050006400 Cyclin Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 235000019988 mead Nutrition 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 238000005096 rolling process Methods 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 0111111 0111 OM HEIR 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/013867 Al 18 January 2018 (18.01.2018) W I PO I PCT (51) International Patent Classification: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, C07D 401/14 (2006.01) A61K 31/506 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A61P 35/00 (2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (21) International Application Number: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. PCT/US2017/042017 (84) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of regional protection available): ARIPO (BW, GH, 13 July 2017 (13.07.2017) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (25) Filing Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (26) Publication Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (30) Priority Data: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/361,852 13 July 2016 (13.07.2016) US KM, ML, MR, NE, SN, TD, TG). (72) Inventors; and Published: (71) Applicants: MARINEAU, Jason, J. [US/US]; 2 MacKin- — with international search report (Art. 21(3)) tosh Street, Franklin, MA 02038 (US). ZAHLER, Robert — before the expiration of the time limit for amending the [US/US]; 5 East Welling Avenue, Pennington, NJ 08534 claims and to be republished in the event of receipt of (US). CIBLAT, Stephane [CA/CA]; 607-408 Rue Saint amendments (Rule 48.2(h)) Jacques, Montreal, Quebec, H2Y 1S2 (CA). WINTER, _ Dana, K. [CA/CA]; 431 Chemin de la Montagne, Rigaud, — Quebec, JOP 1P0 (CA). KABRO, Anzhelika [CA/CA]; = 815, 49e Avenue, Lachine, Quebec, H8T 2T3 (CA). ROY, 815, 49e Avenue, Lachine, = Stephanie [CA/CA]; Quebec, H8T 2T3 (CA). SCHMIDT, Darby [US/US]; 14 Mead Rd., Arlington, MA 02474 CHUAQUI, Claudio (US). 83 Menotomy Rd., Arlington, MA 02476 = [US/US]; (US). MALOJCIC, Goran [HR/US]; 1 Emerson Place, Apt = 7C, Boston, MA 02114 PIRAS, Henri (US). [FR/CA]; 201-6416 Rue de Ecores, Montreal, Quebec, H2G 2J5 (CA). = WHITMORE, Kenneth, Matthew [CA/CA]; 4974-217 = Place de la Savane, Montreal, Quebec, H4P OB1 (CA). — LUND, Kate-Iyn [CA/CA]; 15, 56e Avenue, Lachine, Que- bec, H8T 3B8 SINKO, Bill 37 Wyvern St., (CA). [US/US]; = Roslindale, MA 02131 (US). SPROTT, Kevin [US/US]; 40 = Rolling Lane, Needham, MA 02492 (US). (74) Agent: LARKIN, Angelyn et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US). = = (81) Designated States (unless otherwise indicated, for every = kind AE, AG, AL, AM, of national protection available): AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = — CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, — KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Il IN (54) Title: INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7) of (57) : The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hy- en drates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involv- C ing the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple ----. myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. WD Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity 11 c;;;; ) of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. ei O
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361852P | 2016-07-13 | 2016-07-13 | |
| PCT/US2017/042017 WO2018013867A1 (en) | 2016-07-13 | 2017-07-13 | Inhibitors of cyclin dependnt kinase 7 (cdk7) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900328WA true SG11201900328WA (en) | 2019-02-27 |
Family
ID=59501528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900328WA SG11201900328WA (en) | 2016-07-13 | 2017-07-13 | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| SG10202012466PA SG10202012466PA (en) | 2016-07-13 | 2017-07-13 | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202012466PA SG10202012466PA (en) | 2016-07-13 | 2017-07-13 | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230062491A1 (en) |
| EP (1) | EP3484871B1 (en) |
| JP (2) | JP7058636B2 (en) |
| KR (1) | KR102587758B1 (en) |
| CN (1) | CN110036004A (en) |
| AU (2) | AU2017295863B2 (en) |
| BR (1) | BR112019000716A2 (en) |
| CA (1) | CA3030795A1 (en) |
| ES (1) | ES2954278T3 (en) |
| IL (2) | IL264222B (en) |
| MX (2) | MX2019000527A (en) |
| RU (1) | RU2019103870A (en) |
| SG (2) | SG11201900328WA (en) |
| WO (1) | WO2018013867A1 (en) |
| ZA (1) | ZA201900874B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10913983B2 (en) | 2017-07-18 | 2021-02-09 | University Of South Carolina | Sensitivity markers and uses for CDK7 inhibitors in breast cancers |
| AU2019209470A1 (en) | 2018-01-16 | 2020-08-13 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2019209475A1 (en) | 2018-01-16 | 2020-08-20 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| MX2020011294A (en) * | 2018-04-26 | 2020-11-18 | Pfizer | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors. |
| JP2021151955A (en) * | 2018-05-22 | 2021-09-30 | 株式会社カネカ | METHOD FOR PRODUCING OPTICALLY ACTIVE cis-AMINOPIPERIDINE |
| CN109206427A (en) * | 2018-09-25 | 2019-01-15 | 安徽医科大学 | Aromatic heterocycle vinyl Pyrazolopyrimidines, pharmaceutical preparation and preparation method and application |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| KR20210118812A (en) | 2018-11-01 | 2021-10-01 | 사이로스 파마수티컬스, 인크. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (en) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US20220227734A1 (en) * | 2019-04-23 | 2022-07-21 | Dana-Farber Cancer Institute, Inc. | Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| CR20220066A (en) | 2019-08-14 | 2022-11-28 | Incyte Corp | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CN112430208A (en) * | 2019-08-26 | 2021-03-02 | 东莞市东阳光仿制药研发有限公司 | Preparation method of PF-06651600 intermediate |
| CN115298177A (en) | 2019-10-11 | 2022-11-04 | 因赛特公司 | Bicyclic amines as CDK2 inhibitors |
| CA3156610A1 (en) * | 2019-10-29 | 2021-05-06 | J. Graeme HODGSON | Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN111393415B (en) * | 2020-04-30 | 2020-11-20 | 苏州信诺维医药科技有限公司 | Heteroaromatic nitrile compound and application thereof |
| CN111675708A (en) * | 2020-06-10 | 2020-09-18 | 南京合巨药业有限公司 | Preparation method of 6-cyano-7-azaindole and derivatives thereof |
| CN112661745A (en) * | 2020-07-24 | 2021-04-16 | 浙江同源康医药股份有限公司 | Compounds useful as CDK7 kinase inhibitors and uses thereof |
| CN114133394B (en) * | 2020-08-12 | 2023-12-08 | 赛诺哈勃药业（成都）有限公司 | Compound selectively aiming at activity of cell cycle dependent kinase 12, preparation method and medical application |
| CN114249712A (en) * | 2020-09-24 | 2022-03-29 | 广州费米子科技有限责任公司 | Pyrimidinyl derivatives, method for the production thereof and use thereof |
| WO2022089444A1 (en) * | 2020-10-28 | 2022-05-05 | 恒元生物医药科技(苏州)有限公司 | Nitrogen-containing heterocyclic compound and application thereof |
| CA3200620A1 (en) * | 2020-12-24 | 2022-06-30 | Xiaohui Gu | Aromatic heterocyclic compound, and pharmaceutical composition and application thereof |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| WO2023049691A1 (en) * | 2021-09-23 | 2023-03-30 | Zeno Management, Inc. | Cdk7 inhibitors and methods of treating cancer |
| WO2023091726A1 (en) * | 2021-11-18 | 2023-05-25 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin‑dependent kinase 12 (cdk12) |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| AR128066A1 (en) * | 2021-12-22 | 2024-03-20 | Insilico Medicine Ip Ltd | HETEROCYCLIC PYRIMIDINE COMPOUND AND METHOD OF PREPARATION AND MEDICAL USE THEREOF |
| WO2023116862A1 (en) * | 2021-12-24 | 2023-06-29 | 江苏恒瑞医药股份有限公司 | Hydrogenated indole compound, and preparation method and medical use therefor |
| EP4242195A1 (en) * | 2022-03-09 | 2023-09-13 | EuroChem Antwerpen | Use of pyrazolo[3,4-b]pyridine compounds as nitrification inhibitor |
| WO2024007985A1 (en) * | 2022-07-08 | 2024-01-11 | 成都苑东生物制药股份有限公司 | Pyrimidine derivative, preparation method therefor and use thereof |
| CN115819406B (en) * | 2023-02-24 | 2023-06-02 | 淄博百极荣创医药科技有限公司 | Synthesis method of 3- (4-pyrimidine) -1H-indole compound |
| CN116082337B (en) * | 2023-03-16 | 2023-06-23 | 英矽智能科技(上海)有限公司 | Alkynyl-substituted heterocyclic compounds, process for their preparation and their use in medicine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9604311D0 (en) | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
| WO2006038001A1 (en) * | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| CN101258157A (en) | 2005-05-24 | 2008-09-03 | 阿斯利康(瑞典)有限公司 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| NZ602777A (en) | 2010-04-16 | 2014-07-25 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| EP2796456A1 (en) | 2010-12-09 | 2014-10-29 | Amgen Inc. | Bicyclic compounds as Pim inhibitors |
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| CN103664743B (en) | 2012-09-12 | 2016-09-14 | 上海药明康德新药开发有限公司 | The preparation method of (3S, 4R)-3-amido-4-methyl piperidine-1-carboxylic acid tert-butyl ester |
| WO2014124230A2 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
| EP3057954A2 (en) | 2013-10-18 | 2016-08-24 | Syros Pharmaceuticals, Inc. | Heteromaromatic compounds useful for the treatment of proliferative diseases |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| PT3126352T (en) * | 2014-04-04 | 2018-12-27 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2019209470A1 (en) * | 2018-01-16 | 2020-08-13 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| KR20210118812A (en) * | 2018-11-01 | 2021-10-01 | 사이로스 파마수티컬스, 인크. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
-
2017
- 2017-07-13 BR BR112019000716A patent/BR112019000716A2/en not_active Application Discontinuation
- 2017-07-13 RU RU2019103870A patent/RU2019103870A/en unknown
- 2017-07-13 JP JP2019502013A patent/JP7058636B2/en active Active
- 2017-07-13 SG SG11201900328WA patent/SG11201900328WA/en unknown
- 2017-07-13 SG SG10202012466PA patent/SG10202012466PA/en unknown
- 2017-07-13 EP EP17746235.5A patent/EP3484871B1/en active Active
- 2017-07-13 AU AU2017295863A patent/AU2017295863B2/en active Active
- 2017-07-13 ES ES17746235T patent/ES2954278T3/en active Active
- 2017-07-13 MX MX2019000527A patent/MX2019000527A/en unknown
- 2017-07-13 WO PCT/US2017/042017 patent/WO2018013867A1/en unknown
- 2017-07-13 CN CN201780057760.8A patent/CN110036004A/en active Pending
- 2017-07-13 KR KR1020197004222A patent/KR102587758B1/en active IP Right Grant
- 2017-07-13 CA CA3030795A patent/CA3030795A1/en active Pending
-
2019
- 2019-01-11 MX MX2022005898A patent/MX2022005898A/en unknown
- 2019-01-13 IL IL264222A patent/IL264222B/en unknown
- 2019-02-11 ZA ZA2019/00874A patent/ZA201900874B/en unknown
-
2021
- 2021-11-25 JP JP2021191517A patent/JP7460593B2/en active Active
-
2022
- 2022-02-08 US US17/667,288 patent/US20230062491A1/en not_active Abandoned
- 2022-04-24 IL IL292422A patent/IL292422A/en unknown
- 2022-10-06 AU AU2022246416A patent/AU2022246416A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL264222B (en) | 2022-05-01 |
| RU2019103870A (en) | 2020-08-14 |
| JP2022020860A (en) | 2022-02-01 |
| SG10202012466PA (en) | 2021-01-28 |
| WO2018013867A8 (en) | 2018-11-15 |
| ZA201900874B (en) | 2023-12-20 |
| IL292422A (en) | 2022-06-01 |
| CN110036004A (en) | 2019-07-19 |
| JP7058636B2 (en) | 2022-04-22 |
| ES2954278T3 (en) | 2023-11-21 |
| KR102587758B1 (en) | 2023-10-12 |
| WO2018013867A1 (en) | 2018-01-18 |
| JP7460593B2 (en) | 2024-04-02 |
| AU2017295863B2 (en) | 2022-07-07 |
| IL264222A (en) | 2019-02-28 |
| EP4295852A2 (en) | 2023-12-27 |
| US20230062491A1 (en) | 2023-03-02 |
| RU2019103870A3 (en) | 2020-11-09 |
| MX2019000527A (en) | 2019-08-12 |
| CA3030795A1 (en) | 2018-01-18 |
| MX2022005898A (en) | 2022-06-27 |
| AU2022246416A1 (en) | 2022-11-03 |
| AU2017295863A1 (en) | 2019-02-07 |
| EP3484871B1 (en) | 2023-06-07 |
| KR20190038841A (en) | 2019-04-09 |
| JP2019527217A (en) | 2019-09-26 |
| BR112019000716A2 (en) | 2019-05-07 |
| EP3484871A1 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900328WA (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11202000325UA (en) | Selective inhibitors of nlrp3 inflammasome | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201807708SA (en) | Estrogen receptor modulators | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909841RA (en) | Antitumoral compounds | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201810318RA (en) | Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses | |
| SG11201809799WA (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction |